Secondary leukaemia after treating advanced bladder cancer with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and radiotherapy.
Theodore
C
C
Institut Gustave Roussy, Villejuif, France.
Bayle
C
C
Bernheim
A
A
Wibault
P
P
D000208:Acute Disease; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate